INDICATIONS

REBLOZYL® (luspatercept-aamt) is indicated for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions.

REBLOZYL® (luspatercept-aamt) is indicated for the treatment of anemia without previous erythropoiesis stimulating agent use (ESA-naïve) in adult patients with very low- to intermediate-risk myelodysplastic syndromes (MDS) who may require regular red blood cell (RBC) transfusions.

REBLOZYL® (luspatercept-aamt) is indicated for the treatment of anemia failing an erythropoiesis stimulating agent and requiring 2 or more red blood cell (RBC) units over 8 weeks in adult patients with very low- to intermediate-risk myelodysplastic syndromes with ring sideroblasts (MDS-RS) or with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T).

REBLOZYL is not indicated for use as a substitute for RBC transfusions in patients who require immediate correction of anemia.

Request a Rep

PATIENT IDENTIFICATION: TARGET SECOND-LINE PATIENTs

*For symptomatic anemia in very low- to intermediate-risk MDS with ring sideroblasts (≥15% or ≥5% with an SF3B1 mutation) and with serum EPO ≤500 mU/mL and no del(5q) with or without other cytogenetic abnormalities.

Man standing
Man standing

Consider REBLOZYL for adult patients who1,3:

Consider REBLOZYL for adult patients who1,3:

Are failing on or intolerant to an ESA

Have anemia, requiring 2 or more RBC units over 8 weeks

Have been classified as either:

Very low- to intermediate-risk MDS with ring sideroblasts (RS), defined as MDS with:

  • ≥15% bone marrow (BM) RS
  • ≥5% BM RS with an SF3B1 mutation
OR

Myelodysplastic syndromes/ Myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T)

EPO=erythropoietin; ESA=erythropoiesis-stimulating agent; G-CSF=granulocyte colony-stimulating factor; MDS=myelodysplastic syndromes; MDS-RS=myelodysplastic syndromes with ring sideroblasts; NCCN=National Comprehensive Cancer Network (NCCN®); RBC=red blood cell.

PATIENT IDENTIFICATION: TARGET SECOND-LINE PATIENTs

*For symptomatic anemia in very low- to intermediate-risk MDS with ring sideroblasts (≥15% or ≥5% with an SF3B1 mutation) and with serum EPO ≤500 mU/mL and no del(5q) with or without other cytogenetic abnormalities.

Man standing
Man standing

Consider REBLOZYL for adult patients who1,3:

Consider REBLOZYL for adult patients who1,3:

Are failing on or intolerant to an ESA

Have anemia, requiring 2 or more RBC units over 8 weeks

Have been classified as either:

Very low- to intermediate-risk MDS with ring sideroblasts (RS), defined as MDS with:

  • ≥15% bone marrow (BM) RS
  • ≥5% BM RS with an SF3B1 mutation
OR

Myelodysplastic syndromes/ Myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T)

EPO=erythropoietin; ESA=erythropoiesis-stimulating agent; G-CSF=granulocyte colony-stimulating factor; MDS=myelodysplastic syndromes; MDS-RS=myelodysplastic syndromes with ring sideroblasts; NCCN=National Comprehensive Cancer Network (NCCN®); RBC=red blood cell.

References: 1. REBLOZYL [US Prescribing Information]. Summit, NJ: Celgene Corporation; 2023. 2. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Myelodysplastic Syndromes V.3.2022. © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed October 11, 2022. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. 3. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 20​16;1​2​7(2​0):23​91-24​05.